“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,”
Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature diagnosis, which can rapidly and comprehensively measure an individual’s vaccine response, promising to take much of the initial guesswork out of predicting effective vaccines.
Professor Stephen Albert Johnston and Joseph Barten Legutki, used a mouse model of influenza infection to determine how the immunosignature of a natural infection can be used to discriminate between a protective and non-protective vaccine. The study appears in the October 28 early online edition of the Proceedings of the National Academy of Sciences.
Johnston is driven by the quest to develop disruptive technology that could make health care more effective and affordable. Despite 17 percent of the U.S. GDP tied to health care costs and growing, the U.S. does not get as much value per dollar as other countries (spending the most per capita yet ranking last in efficiency). He believes innovative diagnostic technologies that could determine whether or not an individual would get sick before symptoms appear, as well as the early identification of microbial culprits of infections has high potential for transforming medicine.
“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,” said Johnston, who directs the Center for Innovations and Medicine at the Biodesign Institute “In this work we demonstrate that it may also be useful for screening candidate vaccines.”
Currently, the effectiveness of vaccines is evaluated by looking for the presence a particular type of antibody from the vaccine-generated immune response or by extensive and complicated sets of analyses. The power of the immunosignature is that this effectiveness can be completed in one fell swoop, by using thousands of random molecules aligned on a microscope slide, like the transistors on a computer chip.
“We use an array of 10,000 short peptides, each one about twenty amino acids long, to generate a high degree of specificity and sensitivity for measuring both human, dog, and mouse infections and chronic and genetic diseases,” said Legutki, a faculty in CIM and lead author of the paper. “A subset of these peptides will stand out, based on an individual’s antibody repertoire, and provide a unique pattern, or signature for a given disease.”
In the study, they used a mouse H1N1 flu model system. This included both seasonal forms of influenza or inactive control, as well as several commercially available vaccines that could provide full or partial protection, and asked whether or not the immunosignature could predict vaccine effectiveness. They also examined individual differences among those receiving the same vaccine, and whether the immunosignature profile could have the power to reveal what parts of influenza virus were doing the most harm.
They found that the live and inactive forms of the virus produced different immunosignatures, with different intensities of immune response, yet both contained a core immunosignature of the virus.
Go deeper with Bing News on:
- Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilitieson October 13, 2020 at 10:18 am
The Immunosignature Technology was invented and originally developed by Stephen Albert Johnston, now CEO of Calviri, and his colleagues at ASU. The platform uses hundreds of thousands of ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Fact check: Picture of COVID-19 vaccine production in March 2020 followed development work that began in Januaryon November 27, 2020 at 10:13 am
A photograph of a tube dated March 2020 and labelled as being the Oxford-AstraZeneca COVID-19 vaccine has been shared across social media, with some falsely claiming it is evidence that the ...
- With COVID-19 Vaccine Development Complete, Pharma Companies Look To Next Challengeon November 27, 2020 at 7:00 am
The companies facing unprecedented efforts to deliver a COVID-19 vaccine now face new difficulties in production and distribution.
- Global stocks mixed amid unease about vaccine developmenton November 27, 2020 at 5:57 am
Global stock markets are mixed as questions about the effectiveness of one possible coronavirus vaccine weigh on investor optimism ...
- Asian stocks fall amid unease about vaccine developmenton November 27, 2020 at 1:38 am
Asian stock markets have declined as questions about the effectiveness of one possible coronavirus vaccine weighed on investor optimism ...
- Iran, Russia to cooperate on COVID-19 vaccine developmenton November 27, 2020 at 12:30 am
Spokeswoman for Iranian Ministry of Health and Medical Education announced on Thursday that Tehran and Moscow are to cooperate on COVID-19 vaccine development. Iranian experts will cooperate with the ...